NICE final guidance published for Cimzia
For adults who have failed to respond to, or are unsuitable for, other systemic therapies.
Read More
Tag: certolizumab pegol
FDA label expansion for UCB’s Cimzia
The FDA has approved the drug for a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis.
Read More
AZ’ lung cancer drug Tagrisso backed for first-line use
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
Read More
NICE nod for psoriatic arthritis drugs Cimzia and Cosentyx
Cost regulators for the NHS in England and Wales are recommending UCB’s Cimzia and Novartis’ Cosentyx as treatment options for adults with active psoriatic arthritis.
Read More
UCB launches new Cimzia self-injector in the UK
UCB says it has launched in the UK a new pre-filled self-injecting device for its anti-inflammatory drug Cimzia that was designed in collaboration with patients.
Read More
NICE to expand reach of RA drug Cimzia
NICE has published draft guidance recommending UCB Pharma’s TNF inhibitor Cimzia as an option for severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
